Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ulcerative Colitis

Ulcerative Colitis

Part of Inflammatory Bowel Disease

30 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ulcerative Colitis

188 trials tracked for Ulcerative Colitis: 76 in phase 3 or 4 and 46 with published results. The most-cited published study has 721 citations.

188Trials tracked
76Phase 3 & 4
0Recruiting
46With published results
Phase distribution
Phase 4 13 Phase 3 63 Phase 2 64 Phase 1 10 Other / NA 38
  1. Phase 3 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis Completed · 721 cited
  2. Phase 3 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Completed · 314 cited
  3. Phase 3 Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis Completed · 223 cited
  4. Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease Completed · 190 cited
  5. Phase 4 Predicting Response to Standardized Pediatric Colitis Therapy Completed · 164 cited
  6. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) Completed · 131 cited
Show 44 more trials
  1. Phase 3 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis Completed · 117 cited
  2. Phase 3 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis Completed · 116 cited
  3. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed · 116 cited
  4. Phase 3 A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis Completed · 116 cited
  5. Phase 3 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis Completed · 99 cited
  6. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Completed · 93 cited
  7. Phase 3 A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Completed · 92 cited
  8. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  9. Phase 3 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  10. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  11. Phase 3 A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. Completed · 77 cited
  12. Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis Completed · 75 cited
  13. Phase 3 Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) Completed · 74 cited
  14. Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Completed · 61 cited
  15. Phase 3 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) Completed · 59 cited
  16. Phase 3 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting Completed · 44 cited
  17. Phase 3 Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan Completed · 41 cited
  18. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 38 cited
  19. Phase 4 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed · 37 cited
  20. Phase 3 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis Completed · 33 cited
  21. Phase 4 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed · 32 cited
  22. Phase 3 The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients Completed · 26 cited
  23. Phase 4 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Completed · 25 cited
  24. Phase 4 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed · 24 cited
  25. Phase 4 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed · 23 cited
  26. Phase 3 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Completed · 23 cited
  27. Phase 3 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  28. Phase 3 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  29. Phase 3 An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Completed · 17 cited
  30. Phase 4 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed · 15 cited
  31. Phase 3 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease Completed · 12 cited
  32. Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed · 11 cited
  33. Phase 3 Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission Completed · 7 cited
  34. Phase 3 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Completed · 6 cited
  35. Phase 3 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis Completed · 5 cited
  36. Phase 3 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  37. Phase 3 Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  38. Phase 3 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 3 cited
  39. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 2 cited
  40. Phase 3 BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis Completed
  41. Phase 4 A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Completed
  42. Phase 4 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed
  43. Phase 4 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed
  44. Phase 4 Dose Escalation and Remission (DEAR) Completed

Showing the 50 most-cited and recently-updated of 188 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Single-cell sequencing reveals T cell clonal patterns in healthy donors and ulcerative colitis patients
Gastroenterology
Single-cell sequencing reveals T cell clonal patterns in healthy donors and ulcerative colitis patients T Cells Move Freely in Colon, Not Just in Blood
This observational study analyzed 333,088 T cells from healthy donors and ulcerative colitis (UC) patients using single-cell T cell receptor…
T cells in the colon travel freely across the gut, not just in the blood, reshaping how we understand immune health in conditions like ulcer…
medRxiv Apr 14, 2026
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk
OB/GYN & Women's Health Meta-analysis
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk Does having a C-section raise your child's risk of inflammatory bowel disease?
This systematic review and meta-analysis evaluated the association between mode of delivery and risk of inflammatory bowel disease (IBD) in …
A review of over 13 million births found no link between C-sections and inflammatory bowel disease, easing concerns for parents.
Frontiers Apr 9, 2026
PRO and Serum Biomarker Models Predict Endoscopic Activity in Ulcerative Colitis
Rheumatology Cohort
PRO and Serum Biomarker Models Predict Endoscopic Activity in Ulcerative Colitis Count Your Stools to Spot Flare-Ups Early
A retrospective multicenter cohort study of 297 UC patients developed models using patient-reported outcomes (stool frequency, rectal bleedi…
Counting your daily stools and bleeding can accurately spot ulcerative colitis flare-ups without needing an invasive colonoscopy.
Frontiers Apr 9, 2026
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone
Rheumatology RCT
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone Could adding curcumin to your current ulcerative colitis treatment help you reach remission faster?
This multicenter, double-blind randomized controlled trial enrolled 159 patients with moderate-to-severe ulcerative colitis.
Adding curcumin to ulcerative colitis treatment helped more patients reach symptom remission faster than using standard drugs alone.
Frontiers Apr 8, 2026
Single-cell and spatial technologies reveal UC pathogenesis insights but face sample size and phenotype heterogeneity limits
Allergy & Immunology Meta-analysis
Single-cell and spatial technologies reveal UC pathogenesis insights but face sample size and phenotype heterogeneity limits New tech maps ulcerative colitis cells, but small study groups limit what we know for sure yet
This systematic review evaluated single cell RNA sequencing, spatial transcriptomic, and proteomic technologies in adult ulcerative colitis …
New technology maps exactly which cells drive ulcerative colitis inflammation, helping explain why some patients respond to medicine while o…
Frontiers Apr 6, 2026
Over 100 agents in development for moderate to severe ulcerative colitis, with early remission data for one class
Gastroenterology
Over 100 agents in development for moderate to severe ulcerative colitis, with early remission data for one class Many new ulcerative colitis drugs are in development, with early trial results for one type
A review describes a pipeline of over 100 investigational agents for moderate to severe ulcerative colitis.
New ulcerative colitis drugs show over 25% remission in early trials, offering hope for the 20% of patients hospitalized within five years o…
Frontiers Apr 1, 2026

Questions about Ulcerative Colitis

How does the gut bacteria diversity in ulcerative colitis compare to healthy controls?

Ulcerative colitis patients consistently show reduced gut bacterial diversity (lower Shannon index) and altered composition compared to healthy controls, with depletion of beneficial butyrate-producing bacteria and increases in certain pro-inflammatory groups.

Full answer →
Is there a link between NF-kB pathway inhibition and treating ulcerative colitis?

Yes, inhibiting the NF-κB pathway is a key treatment strategy for ulcerative colitis, as it reduces inflammation and may prevent cancer progression.

Full answer →
Are there specific biomarkers that can accurately diagnose ulcerative colitis in a new patient?

Yes, three biomarkers (ARHGEF3, S100A8, RHOU) show high diagnostic accuracy for ulcerative colitis, and bile acid ratios are also promising noninvasive markers.

Full answer →
Can enteral nutrition therapy help achieve remission in patients with ulcerative colitis?

Enteral nutrition therapy may help achieve remission in ulcerative colitis, with studies showing clinical remission rates around 60% and benefits in acute severe cases, but evidence is stronger for Crohn's disease.

Full answer →